Am J Pharmacol | Volume 1, Issue 1 | Review Article | Open Access
Izzettin Hatip-Al-Khatib1, Funda Bölükbaşi Hatip1 and Y Matsunaga2*
1Department of Medical Pharmacology, Pamukkale University, Turkey
2Department of Medical Pharmacology, Tokushima Bunri University, Japan
*Correspondance to: Y Matsunaga
Fulltext PDFThe Renin-Angiotensin (Ang) System (RAS) is pleotropic machinery, contains members with different activities. New substrates, such as Ang-(1-7) and Ang-(3-7), of vascular and tissue source are being added to RAS. These new comers counter balance/oppose the effects of the traditional previously identified Ang I & II. Ang-(1-7) is identified as a biologically active member of RAS. Ang- (1-7) is synthesized from Ang II by the action of angiotensin converting enzyme ACE2, and acts on its G protein-coupled Mas receptors (MasR) and Mas-related G-protein-coupled receptor (Mrg-D) forming its own ACE2/Ang-(1-7)/Mas Axis (AAMA). This axis counteracts many of the Ang II-AT1 activities, especially vasoconstriction, inflammation and proliferation. A growing body of evidence supports AAMA presence in brain, and the role it plays in conditions other than the renal and cardiovascular diseases, such as Alzheimer’s disease, Parkinson’s disease, ageing, menopause etc. There are different and even conflicting results reported acceleratory or preventive effects of RAS components, angiotensin receptor antagonists (ARB) and ACE Inhibitors (ACEI) in AD. Moreover, there is also a difference between ARBs and ACEIs in this regard. Here, we review the importance of the AAMA axis and other protective arms of RAS with emphasis on the role of this axis in brain function, various neurodegenerative diseases and patients receiving ACEIs and ARBs.
Hatip-Al-Khatib I, Hatip FB, Matsunaga Y. The Protective Tributary Angiotensin Members of Renin-Angiotensin System Display Beneficial Effects in the Central Nervous System Disorders. Am J Pharmacol. 2018;1(1):1001.